Develops antibodies for cancer and autoimmune diseases.
Jun 2026Revenue $105M/yrExpenses $321M/yr
No trendCash runway ≈ 3 months from Jun 2026
Figures by year
When will Xencor be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $105M and expenses $321M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $126M | $303M | −$178M |
| Dec 2024 | $110M | $289M | −$178M |
| Dec 2023 | $175M | $307M | −$132M |
| Dec 2022 | $165M | $247M | −$82.5M |
| Dec 2021 | $275M | $231M | $43.8M |
| Dec 2020 | $123M | $199M | −$76.8M |
| Dec 2019 | $157M | $143M | $13.8M |
| Dec 2018 | $40.6M | $120M | −$79.4M |
| Dec 2017 | $46.1M | $89.3M | −$43.1M |
| Dec 2016 | $109M | $65.0M | $44.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.